99% CAS 58-14-0 Pyrimethamine Antimalarial Pyrimethamine

• Customization: Available
• Powder: Yes
• Customized: Negotiable
• Model NO.: QS-Pyrimethamine
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Pyrimethamine
• Name: Pyrimethamine Powder
• Appearance: White Powder
• Colour: White
• Grade: Pharmaceutical Grade
• Assay: >99%
• Application: API
• Specific: COA
• Test Method: HPLC
• CAS: 58-14-0
• Mf: C12h13cln4
• MW: 248.71142
• Melting Point: 233-234c
• Boiling Point: 491.5c At760mmhg
• Density: 1.305
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS- Pyrimethamine
• Origin: Xian
• Production Capacity: 1000kg/Month

Product Description

99% CAS 58-14-0 Pyrimethamine Antimalarial Pyrimethamine

Product Description

Product Details

Product Name	Pyrimidine
Appearance	Pyrimidine Powder
Assay	99%
MW	248.71142
MF	C12H13ClN4

Pyrimidine exerts anti malaria and anti Toxoplasma effects through a dual mechanism (inhibition of DHFR and Mdr-1), making it a core drug for malaria prevention and combined treatment of Toxoplasma encephalitis. Strict monitoring of blood toxicity is necessary in clinical practice, and priority should be given to combining with sulfonamide drugs to enhance efficacy. It is commonly used in research on drug resistance and folate metabolism.

Application&Function

The pharmacological effects of Pyrimethamine
1. Pharmacological mechanism of action
Inhibition of dihydrofolate reductase (DHFR): By selectively inhibiting the DHFR enzyme of protozoa such as malaria parasites and Toxoplasma gondii, the synthesis of tetrahydrofolate is blocked, interfering with DNA/RNA replication and protein metabolism, leading to pathogen death.
Inhibition of multidrug resistance transporter protein (Mdr-1/P-glycoprotein): reduces intracellular drug efflux, enhances intracellular concentration and efficacy of other antimalarial or chemotherapy drugs.
2. Indications
Malaria:
Used for etiological prevention (such as prevention before entering malaria endemic areas) and anti recurrence treatment (in combination with sulfonamide drugs, such as sulfadoxine).
It has a killing effect on extracellular parasites of Plasmodium vivax, Plasmodium vivax, and Plasmodium falciparum.
Toxoplasmosis: combined with sulfadiazine for the treatment of Toxoplasma encephalitis in immunocompromised patients (such as AIDS).
3. Combination therapy enhances efficacy
Combined with sulfonamide drugs (such as sulfadoxine), a synergistic anti malarial effect is achieved by double blocking the folate synthesis pathway (sulfonamide inhibits dihydrofolate synthase, and ethambutol inhibits DHFR).
4. Other applications
Research field:
Used for studying multidrug resistance mechanisms and developing reversal agents (such as inhibiting Mdr-1/P-glycoprotein).
As a DHFR inhibitor, it is used for research on tumor cell metabolism and drug resistance.
5. Precautions
Toxicity risk: Long term or high-dose use may cause bone marrow suppression (such as megaloblastic anemia) and gastrointestinal reactions (nausea, vomiting).
Contraindications: Prohibited in early pregnancy (teratogenic risk); Patients with severe liver and kidney dysfunction need to adjust their dosage.
Stability: The composite suspension needs to be stored in refrigeration (2-8 ºC), and the valence decreases over time at 37 ºC.

 

Specification